Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that one-year clinical outcomes with the DurAVR^® Transcatheter Heart Valve (THV) will be presented by Rishi Puri MD PhD, at TCT^® 2025 – The 37^th Annual Transcatheter Cardiovascular Therapeutics^® Conference, taking place in San Francisco, California, October 25-28, 2025.